Needle Moving as Stock Balloons in Quarter: Cytokinetics, Incorporated (NASDAQ:CYTK)

Investors who took positions in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) are riding high as the stock has performed solidly over the past few months, marking a 1.80% increase for the quarter.  Drilling down, the stock is 39.73% for the past month and 12.16% for the week.  

Session Update

At the session level, shares of Cytokinetics, Incorporated (NASDAQ:CYTK) moved 5.51% from the open. The most recent bid on the stock was registered at $12.45. Further, company shares have been seen trading -5.54% off of the 52 week high and 107.50% away from the 52 week low. Narrowing in further, the stock has been recently noted at 5.06% away from the 50 day high and 46.30% separated from the 50 day low.

Analyst Views

Wall Street brokerage firms that regularly cover the stock have provided price targets and recommendations on Cytokinetics, Incorporated (NASDAQ:CYTK). According to First Call, the consensus price target for the company is $17.75. The consensus recommendation provided by analysts is currently 1.80. This number is based on a scale from 1 to 5. Analysts rating the company a 1 or 2 indicate a Buy recommendation. Analysts rating the company a 4 or 5 indicate a Sell recommendation. Analysts rating the company a 3 indicate a Hold recommendation.

The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs.  Where quoted, past performance is not indicative of future performance.

COMMENTS